| For: | Pramanik S, Pal P, Ray S. Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies. World J Methodol 2024; 14(2): 91319 [PMID: 38983664 DOI: 10.5662/wjm.v14.i2.91319] |
|---|---|
| URL: | https://www.wjgnet.com/2222-0682/full/v14/i2/91319.htm |
| Number | Citing Articles |
| 1 |
Hisayuki Katsuyama, Seiichi Horinaka, Mariko Hakoshima, Hiroki Adachi, Hidekatsu Yanai. Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients. Journal of Clinical Medicine 2024; 13(16) doi: 10.3390/jcm13164929
|
| 2 |
Nawfal Hasan Siam, Nayla Nuren Snigdha, Noushin Tabasumma, Irin Parvin. Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies. Reviews in Cardiovascular Medicine 2024; 25(12) doi: 10.31083/j.rcm2512436
|
| 3 |
Marcio J Concepción-Zavaleta, Jenyfer M Fuentes-Mendoza, Jhean G Gonzáles-Yovera, Gemma Y Ruvalcaba-Barbosa, Leonardo D Cura-Rodríguez, Josué S González-Rodríguez, Luis A Concepción-Urteaga, Aranza I Pérez-Reyes, Juan Eduardo Quiroz-Aldave, José Paz-Ibarra. Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. World Journal of Gastroenterology 2025; 31(37): 111435 doi: 10.3748/wjg.v31.i37.111435
|
| 4 |
Monika Gupta, Jitendra Shukla. Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. The Indian Journal of Medical Research 2026; 163 doi: 10.25259/IJMR_2041_2025
|
| 5 |
Yuantao Zhang, Xianglong Liu, Yunkai Hu, Xuqiu Cheng, Wenyuan Liu, Ziwei Tian, Yan Zhang, Guimei Chen, Bing Hu, Changliu Liang, Chunmei Liang, Fangbiao Tao, Linsheng Yang. Association of nitrogen dioxide with non-alcoholic fatty liver disease in Chinese rural older adults: The mediating role of fasting plasma glucose. Environmental Research 2026; 290 doi: 10.1016/j.envres.2025.123518
|
| 6 |
Lindsey A. Miles, Hongdong Bai, Sagarika Chakrabarty, Nagyung Baik, Yuqing Zhang, Robert J. Parmer, Fahumiya Samad. Macrophage Plg-RKT expression promotes diet-induced obesity and metabolic dysfunction-associated steatotic liver disease. Journal of Thrombosis and Haemostasis 2026; 24(1) doi: 10.1016/j.jtha.2025.09.020
|
| 7 |
Yibin Cai, Jiayin Li, Shenyu Chen, Hui Zhang, Jie Tan, Hao Li, Shuyuan Zhang, Boran Li, Qin Wei, Chenshi Lin, Xuesong Zhong, Xiuhua You, Chao Qin, Chao Teng, Jie Liu. Liver fibrosis: Pathogenesis and innovative nanoparticle-based therapeutic strategies. International Journal of Pharmaceutics: X 2026; 12 doi: 10.1016/j.ijpx.2026.100596
|
| 8 |
Muhammad Naqash, Abdullah Tariq, Shazma Shayan, Sadaf Manzoor Sargani, Muhammad Asad Raza, Nasar Nasrullah Khan, Aiman Balouch, Rana Muhammad Usama, Khabab Abbasher Hussien Mohamed Ahmed, Dirk Uhlmann. Fibroblast Growth Factor 21 Analogues Improve Fibrosis in Metabolic Dysfunction–Associated Steatohepatitis: An Updated Systematic Review and Meta‐Analysis. International Journal of Hepatology 2026; 2026(1) doi: 10.1155/ijh/7391450
|